SCHEMBL14960519

SCHEMBL14960519

Cc1cccc(F)c1C(=O)N1CCC[C@H](C(=O)Nc2cccc(C(C)(C)C)c2)[C@@H]1c1ccc(CCC(C)(C)O)cc1

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAPK14 Q16539 1/20 0.37
▸ UBE2M P61081 2/20 0.36
▸ DCUN1D1 Q96GG9 2/20 0.36
▸ ALDH1A1 P00352 2/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ RXFP1 Q9HBX9 1/20 0.35
▸ CCR1 P32246 1/20 0.35
▸ RHOA P61586 2/20 0.34
▸ GCGR P47871 1/20 0.34
▸ GIPR P48546 1/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ CYP2C9 P11712 1/20 0.34
▸ EPHX2 P34913 1/20 0.34
▸ NPSR1 Q6W5P4 1/20 0.34
▸ TDP1 Q9NUW8 1/20 0.34
▸ USP2 O75604 1/20 0.34
▸ CASP3 P42574 1/20 0.34
▸ ACKR3 P25106 2/20 0.34
▸ GAA P10253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18790204 1.00 MAPK14 (0.37) MAPK14UBE2MDCUN1D1ALDH1A1HSD17B10
SCHEMBL17805437 1.00 MAPK14 (0.37) MAPK14UBE2MDCUN1D1ALDH1A1HSD17B10
SCHEMBL21163857 1.00 MAPK14 (0.37) MAPK14UBE2MDCUN1D1ALDH1A1HSD17B10
SCHEMBL14959097 0.95 MAPK14 (0.38) MAPK14UBE2MDCUN1D1ALDH1A1HSD17B10
SCHEMBL15088237 0.95 RXFP1 (0.37) MAPK14UBE2MDCUN1D1ALDH1A1RXFP1
SCHEMBL18609279 0.94 MAPK14 (0.36) MAPK14UBE2MDCUN1D1ALDH1A1HSD17B10
SCHEMBL14960531 0.94 MAPK14 (0.36) MAPK14UBE2MDCUN1D1ALDH1A1HSD17B10
SCHEMBL12176260 0.93 UBE2M (0.37) MAPK14UBE2MDCUN1D1ALDH1A1HSD17B10
SCHEMBL14959101 0.93 MAPK14 (0.37) MAPK14UBE2MDCUN1D1ALDH1A1HSD17B10
SCHEMBL21163622 0.92 MAPK14 (0.37) MAPK14UBE2MDCUN1D1ALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230102258-A1 C5AR ANTAGONISTS CHEMOCENTRYX, INC. 2023-03-30 — — US disclosed
EP-3508477-B1 C5AR ANTAGONISTS CHEMOCENTRYX INC (US) 2021-11-10 — — EP disclosed
US-20170114017-A1 C5AR ANTAGONISTS CHEMOCENTRYX, INC. 2017-04-27 — — US disclosed
US-20170065604-A1 C5aR ANTAGONISTS CHEMOCENTRYX, INC. 2017-03-09 — — US disclosed
US-9573897-B2 C5AR antagonists CHEMOCENTRYX, INC. (US) 2017-02-21 — — US disclosed
EP-3078658-A1 C5AR ANTAGONISTS ChemoCentryx, Inc. (US) 2016-10-12 — — EP disclosed
US-20160229802-A1 C5AR ANTAGONISTS CHEMOCENTRYX, INC. 2016-08-11 — — US disclosed
EP-2381778-B1 C5AR ANTAGONISTS CHEMOCENTRYX INC (US) 2016-06-08 — — EP disclosed
US-9126939-B2 C5AR antagonists CHEMOCENTRYX, INC. 2015-09-08 — — US disclosed
US-20150141425-A1 C5aR ANTAGONISTS CHEMOCENTRYX, INC. 2015-05-21 — — US disclosed
US-8906938-B2 C5aR antagonists CHEMOCENTRYX, INC. (US) 2014-12-09 — — US disclosed
US-20130172347-A1 C5AR ANTAGONISTS CHEMOCENTRYX, INC. 2013-07-04 — — US disclosed
US-8445515-B2 C5aR antagonists CHEMOCENTRYX, INC. (US) 2013-05-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150141425-A1 C5aR ANTAGONISTS C5AR1, C5AR2, C3AR1 MAPK14 3989/4885UBE2M 4268/4885DCUN1D1 1926/4885
US-20170114017-A1 C5AR ANTAGONISTS C5AR1, C5AR2, C3AR1 MAPK14 3989/4885UBE2M 4268/4885DCUN1D1 1926/4885
US-20160229802-A1 C5AR ANTAGONISTS C5AR1, C5AR2, C3AR1 MAPK14 3989/4885UBE2M 4268/4885DCUN1D1 1926/4885
US-20230102258-A1 C5AR ANTAGONISTS C5AR1, C5AR2, C3AR1 MAPK14 3989/4885UBE2M 4268/4885DCUN1D1 1926/4885
US-20130172347-A1 C5AR ANTAGONISTS C5AR1, C5AR2, C3AR1 MAPK14 3989/4885UBE2M 4268/4885DCUN1D1 1926/4885
US-20170065604-A1 C5aR ANTAGONISTS C5AR1, C5AR2, C3AR1 MAPK14 3832/4885UBE2M 4188/4885DCUN1D1 2149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback